Learned helplessness

Worried about 2023? It might all be in your head - New study delves into the psychological basis of a fear of the future

Retrieved on: 
Tuesday, January 10, 2023

MONTREAL, Jan. 10, 2023 /PRNewswire-PRWeb/ -- The state of the economy, resurging COVID cases, military conflicts, and the deteriorating health of the planet has many people feeling rather despondent these days and perhaps even a little fatalistic about what the new year might bring. But what lies at the root of this doom and gloom mindset? It likely wouldn't surprise most people that extreme doomsayers are more likely to be pessimists, but according to a study by PsychTests.com, they also have a propensity for stubbornness and tend to lack effective coping skills.

Key Points: 
  • > 58% are afraid that if they get their hopes up, they will be heartbreakingly disappointed (compared to 17% of Level-headers).
  • > 46% struggle to bounce back from disappointments, setbacks, and failures (compared to 10% of Level-headers).
  • > 72% tend to obsessively dissect and over-analyze situations, creating problems where there are none (compared to 24% of Level-headers).
  • If you fixate on all the bad that is going on, you will never be able to recognize the good.

EQS-News: Reset Pharmaceuticals Appoints Innes Meldrum as President and Chief Executive Officer

Retrieved on: 
Sunday, January 22, 2023

New York, NY, January 5, 2023 - Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.

Key Points: 
  • New York, NY, January 5, 2023 - Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.
  • Innes Meldrum has nearly 30 years of global experience in the biotechnology and technology industries, having most recently served as Senior Vice President and Chief Commercial Officer for Otsuka Pharmaceuticals North America.
  • “We are delighted to have Innes join Reset Pharma as CEO,” said Philip Taub, Chair of the Board.
  • I warmly welcome Innes and look forward to working with him and the entire Reset Pharma team.

Reset Pharmaceuticals Appoints Innes Meldrum as President and Chief Executive Officer

Retrieved on: 
Thursday, January 5, 2023

NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.

Key Points: 
  • NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.
  • Innes Meldrum has nearly 30 years of global experience in the biotechnology and technology industries, having most recently served as Senior Vice President and Chief Commercial Officer for Otsuka Pharmaceuticals North America.
  • “We are delighted to have Innes join Reset Pharma as CEO,” said Philip Taub, Chair of the Board.
  • I warmly welcome Innes and look forward to working with him and the entire Reset Pharma team.

Autobahn Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ABX-002 for the Treatment for Major Depressive Disorder

Retrieved on: 
Tuesday, November 29, 2022

Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced the initiation of dosing in the companys Phase 1 clinical trial of ABX-002 in healthy volunteers.

Key Points: 
  • Autobahn Therapeutics, a biotechnology company focused on restoring hope for people affected by CNS disorders, today announced the initiation of dosing in the companys Phase 1 clinical trial of ABX-002 in healthy volunteers.
  • ABX-002 is a potent and selective, brain-boosting thyroid receptor beta (TR) agonist that Autobahn is evaluating as a potential adjunctive treatment for people with major depressive disorder (MDD) who are experiencing an inadequate response to their antidepressant.
  • We look forward to advancing ABX-002 in the clinic as we further our understanding of its potential impact for patients.
  • Inadequate Response to Treatment in Major Depressive Disorder: Augmentation and Adjunctive Strategies.

Global Times: Inner Mongolia's 'grain king' committed to promoting agricultural technology, confident in China's food security in facing farmers' expectations

Retrieved on: 
Tuesday, November 8, 2022

"The report to the 20th CPC National Congress once again has made food security and rural revitalization as an important priority.

Key Points: 
  • "The report to the 20th CPC National Congress once again has made food security and rural revitalization as an important priority.
  • Mei's sense of accomplishment also comes from her judgment of the current stable and progressive food security situation in China.
  • At the grass-roots level, she has personally felt the efforts and determination of the CPC in ensuring food security.
  • "The current emphasis on national food security is not a hasty response to the crisis; our country has always taken precautions.

EQS-News: Reset Pharmaceuticals announces appointment of neuroscience industry leader Lisa Deschamps to the Board of Directors

Retrieved on: 
Thursday, November 3, 2022

Ms. Deschamps is a highly experienced pharmaceutical executive who has worked at Board and senior management levels with global responsibilities.

Key Points: 
  • Ms. Deschamps is a highly experienced pharmaceutical executive who has worked at Board and senior management levels with global responsibilities.
  • Before this, she was Worldwide Business Head, Neuroscience at Novartis, where she was responsible for the development and commercialization of the neuroscience portfolio.
  • She has been involved in more than a dozen successful product approvals and launches in many therapeutic areas, including in neuroscience.
  • We are very happy to welcome Lisa to the Board, said Philip Taub, Chair of the Board of Reset Pharma.

Reset Pharmaceuticals announces appointment of neuroscience industry leader Lisa Deschamps to the Board of Directors

Retrieved on: 
Wednesday, November 2, 2022

Ms. Deschamps is a highly experienced pharmaceutical executive who has worked at Board and senior management levels with global responsibilities.

Key Points: 
  • Ms. Deschamps is a highly experienced pharmaceutical executive who has worked at Board and senior management levels with global responsibilities.
  • Before this, she was Worldwide Business Head, Neuroscience at Novartis, where she was responsible for the development and commercialization of the neuroscience portfolio.
  • She has been involved in more than a dozen successful product approvals and launches in many therapeutic areas, including in neuroscience.
  • We are very happy to welcome Lisa to the Board, said Philip Taub, Chair of the Board of Reset Pharma.

The CW Network Launches “Dare to Love, Defy Hate” With Song From Music Icon Stevie Wonder and New Mental Health Initiative Following United States Surgeon General Advisory on Youth Mental Health Crisis

Retrieved on: 
Monday, October 10, 2022

The CW Network is honored to partner with the United States Surgeon General to launch this incredibly important national conversation and movement around youth mental health, said Dennis Miller, President, The CW Network.

Key Points: 
  • The CW Network is honored to partner with the United States Surgeon General to launch this incredibly important national conversation and movement around youth mental health, said Dennis Miller, President, The CW Network.
  • We are also tremendously grateful to the legendary Stevie Wonder for the use of his song in this initiative.
  • Additional public service announcements addressing other areas of mental health will debut in the coming weeks as a part of the ongoing initiative.
  • It is clear that this was a crisis before the pandemic began, but COVID-19 added to the pre-existing challenges that Americas youth face.

Autobahn Therapeutics Announces Successful Financing to Support Strategic Advancement of ABX-002 for Treatment Resistant Depression

Retrieved on: 
Thursday, September 8, 2022

TRD is a subsegment of major depressive disorder (MDD) and is characterized by an inadequate response to treatment after using two or more approved medications.

Key Points: 
  • TRD is a subsegment of major depressive disorder (MDD) and is characterized by an inadequate response to treatment after using two or more approved medications.
  • Extensive clinical precedent provides strong evidence of thyroid hormones role in depression, suggesting that its augmentation could lead to jump-starting responses in people taking antidepressants.
  • ABX-002 is expected to augment antidepressant treatments by potentiating the beneficial effects of these drugs on monoaminergic signaling.
  • Autobahn plans to initiate a Phase 1 single- and multiple-ascending dose trial with ABX-002 in healthy volunteers in the second half of 2022.

Sarah Thomas Joins The Eden Alternative Board of Directors

Retrieved on: 
Friday, August 19, 2022

ROCHESTER, N.Y., Aug. 19, 2022 /PRNewswire/ -- Today, The Eden Alternative, a nonprofit organization improving the landscape of aging services, announced the addition of Sarah Thomas to the Board of Directors. The Eden Alternative – in operation for more than 25 years – is continuing a recent run of rapid innovation; the addition of Thomas to the Board enhances the organization's ability to lead in the changing landscape of technology and aging.

Key Points: 
  • ROCHESTER, N.Y., Aug. 19, 2022 /PRNewswire/ -- Today, The Eden Alternative, a nonprofit organization improving the landscape of aging services, announced the addition of Sarah Thomas to the Board of Directors.
  • Thomas joins the Board of Directors as an accomplished leader of innovation and as an expert in aging with more than 20 years dedicated to transforming the aging experience.
  • Thomas joins the Board of Directors as The Eden Alternative modernizes its services and tools to meet the needs of practitioners and communities deeply impacted by the global pandemic, staffing shortages and the slow pace of innovation.
  • Under the leadership of CEO Patrick Bultema, The Eden Alternative has refactored much of its core intellectual property and services.